Advertisement

Targeted Oncology

, Volume 14, Issue 1, pp 39–41 | Cite as

BI 853520, a FAK-Simile of Prior FAK Inhibitors?

  • Rachael Chang Lee
  • Hui K. GanEmail author
Commentary
  • 43 Downloads

In this issue of Targeted Oncology, the BI 853520 investigators present three complementary studies of BI 853520 that investigate this drug in both Western and Eastern patient populations, as well as investigating the effects of food and drug formulation on drug absorption [1, 2, 3]. It is the latest in the field of similar compounds against focal adhesion kinase (FAK), a pre-clinically promising target for cancer therapy. FAK is a multifunctional cytoplasmic tyrosine kinase that has been shown to play an important role in the regulation of proliferation, metastasis, angiogenesis and tumour microenvironment signalling [4]. Some of these effects are mediated through kinase-dependent signalling and others through kinase-independent signalling [1, 4]. Overexpression of FAK has been observed in multiple different malignancies and may contribute to tumour progression and aggressiveness [5]. Pre-clinically, inhibition of FAK has been shown to inhibit tumour growth [4, 5]. Anti-cancer drugs...

Notes

Compliance with Ethical Standards

Funding

No external funding was used in the preparation of this article.

Conflict of interest

Rachael Chang Lee and Hui Gan declare that they have no conflicts of interest that might be relevant to the contents of this article.

References

  1. 1.
    de Jonge MJA, Steeghs N, Lolkema MP, Hotte SJ, Hirte HW, van der Biessen DAJ, et al. Phase I Study of BI 853520, an inhibitor of focal adhesion kinase, in patients with advanced or metastatic nonhematologic malignancies. Targ Oncol. 2019.  https://doi.org/10.1007/s11523-018-00617-1.Google Scholar
  2. 2.
    Doi Y, Yang JC-H, Shitara K, Naito Y, Cheng A-L, Sarashina A, et al. Phase I study of BI 853520, an inhibitor of focal adhesion kinase, in patients with advanced or metastatic nonhematologic malignancies. Targ Oncol. 2019.  https://doi.org/10.1007/s11523-019-00620-0.Google Scholar
  3. 3.
    Verheijen RB, Van der Biessen DAJ, Hotte SJ, Siu LL, Spreafico A, De Jonge MJA, et al. Randomized, open-label, crossover studies evaluating the effect of food and liquid formulation on the pharmacokinetics of the novel focal adhesion kinase (FAK) inhibitor. Targ Oncol. 2019.  https://doi.org/10.1007/s11523-018-00618-0.Google Scholar
  4. 4.
    Sulzmaier FJ, Jean C, Schlaepfer DD. FAK in cancer: mechanistic findings and clinical applications. Nat Rev Cancer. 2014;14:598.  https://doi.org/10.1038/nrc3792.CrossRefGoogle Scholar
  5. 5.
    Shanthi E, Krishna MH, Arunesh GM, Venkateswara Reddy K, Sooriya Kumar J, Viswanadhan VN. Focal adhesion kinase inhibitors in the treatment of metastatic cancer: a patent review. Expert Opin Ther Pat. 2014;24(10):1077–100.  https://doi.org/10.1517/13543776.2014.948845.CrossRefGoogle Scholar
  6. 6.
    Infante JR, Camidge DR, Mileshkin LR, Chen EX, Hicks RJ, Rischin D, et al. Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors. J Clin Oncol. 2012;30(13):1527–33.  https://doi.org/10.1200/jco.2011.38.9346.CrossRefGoogle Scholar
  7. 7.
    Soria JC, Gan HK, Blagden SP, Plummer R, Arkenau HT, Ranson M, et al. A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors. Ann Oncol. 2016;27(12):2268–74.  https://doi.org/10.1093/annonc/mdw427.CrossRefGoogle Scholar
  8. 8.
    Jones SF, Siu LL, Bendell JC, Cleary JM, Razak AR, Infante JR, et al. A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors. Invest New Drugs. 2015;33(5):1100–7.  https://doi.org/10.1007/s10637-015-0282-y.CrossRefGoogle Scholar
  9. 9.
    Gerber DE, Camidge DR, Morgensztern D, Cetnar J, Kelly RJ, Ramalingam SS et al. Phase II study of Defactinib, VS-6063, a Focal Adhesion Kinase (FAK) Inhibitor in Patients with KRAS Mutant Non-Small Cell Lung Cancer (NSCLC). In: World conference on lung cancer; Sep 6–9, 2015; Denver. Colorado, USA, 2015.Google Scholar
  10. 10.
    Oncology V. Verastem Stops Enrollment Due to Futility in the COMMAND Study of VS-6063 for the Treatment of Malignant Pleural Mesothelioma. 2015. http://investor.verastem.com/phoenix.zhtml?c=250749&p=irol-newsArticle&ID=2090793. Accessed 20 Jan 2019.
  11. 11.
    Lv PC, Jiang AQ, Zhang WM, Zhu HL. FAK inhibitors in cancer, a patent review. Expert Opin Ther Pat. 2018;28(2):139–45.  https://doi.org/10.1080/13543776.2018.1414183.CrossRefGoogle Scholar
  12. 12.
    Shapiro IM, Kolev VN, Vidal CM, Kadariya Y, Ring JE, Wright Q, et al. Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship. Sci Transl Med. 2014;6(237):237ra68.  https://doi.org/10.1126/scitranslmed.3008639.CrossRefGoogle Scholar
  13. 13.
    Hirt UA, Waizenegger IC, Schweifer N, Haslinger C, Gerlach D, Braunger J, et al. Efficacy of the highly selective focal adhesion kinase inhibitor BI 853520 in adenocarcinoma xenograft models is linked to a mesenchymal tumor phenotype. Oncogenesis. 2018;7(2):21.  https://doi.org/10.1038/s41389-018-0032-z.CrossRefGoogle Scholar
  14. 14.
    Golubovskaya V, Ho B, Stright A, Zajac-Kaye M, Hochwald SN, Cance WG, et al. Targeting Y397 FAK scaffolding compared with FAK kinase inhibition: efficacy and specificity for tumor cells. J Clin Oncol. 2013;31(Suppl 15):e13547.Google Scholar
  15. 15.
    Patel MR, Infante JR, Moore KN, Keegan M, Poli A, Padval M et al. Phase 1/1b study of the FAK inhibitor defactinib (VS-6063) in combination with weekly paclitaxel for advanced ovarian cancer. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2013 Oct 19-23; Boston, MA. Philadelphia (PA): AACR. Molecular Cancer Therapeutics. 2013;12.Google Scholar
  16. 16.
    Howe GA, Xiao B, Zhao H, Al-Zahrani KN, Hasim MS, Villeneuve J, et al. Focal adhesion kinase inhibitors in combination with erlotinib demonstrate enhanced anti-tumor activity in non-small cell lung cancer. PLoS One. 2016;11(3):e0150567.  https://doi.org/10.1371/journal.pone.0150567.CrossRefGoogle Scholar
  17. 17.
    Arkenau H-T, Gazzah A, Plummer R, Blagden SP, Mak G, Soria J-C, et al. A phase Ib dose-escalation study of GSK2256098 (FAKi) plus trametinib (MEKi) in patients with selected advanced solid tumors. J Clin Oncol. 2015;33(15_suppl):2593.  https://doi.org/10.1200/jco.2015.33.15_suppl.2593.CrossRefGoogle Scholar
  18. 18.
    Ring JE, Li Y, Shapiro IM, Wang Y, Weaver DT, Pachter JA. FAK/PYK2 inhibitors defactinib and VS-4718 enhance immune checkpoint inhibitor efficacy [abstract]. In: Proceedings of the AACR-NCI-EORTC international conference: molecular targets and cancer therapeutics; 2015 Nov 5–9; Boston, MA. Philadelphia (PA): AACR. Molecular Cancer Therapeutics. 2015;14.Google Scholar
  19. 19.
    Wang-Gillam A, Lockhart AC, Tan BR, Suresh R, Lim K-H, Ratner L, et al. Phase I study of defactinib combined with pembrolizumab and gemcitabine in patients with advanced cancer. J Clin Oncol. 2018;36(15_suppl):2561.  https://doi.org/10.1200/jco.2018.36.15_suppl.2561.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Olivia Newton John Cancer CentreHeidelbergAustralia

Personalised recommendations